{"nctId":"NCT00802672","briefTitle":"Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis","startDateStruct":{"date":"2003-12"},"conditions":["Tinea Pedis"],"count":561,"armGroups":[{"label":"Test Product","type":"EXPERIMENTAL","interventionNames":["Drug: Ciclopirox Olamine Cream"]},{"label":"Reference Product","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Loprox Cream 0.77%"]},{"label":"Vehicle Product","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Ciclopirox Olamine Cream","otherNames":[]},{"name":"Loprox Cream 0.77%","otherNames":["Loprox Cream"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female at least 10 years of age, and otherwise healthy\n* Clinically and mycologically confirmed diagnosis of symptomatic tinea pedis\n* In good health with no clinically significant disease that might have interfered with study evaluations\n* Study participant or legal guardian was willing and able to read and sign an IRB approved ICF, which included agreement to comply with all study requirements as indicated in the protocol. For subjects 10 to 17 years of age, an assent form for minors was completed.\n\nExclusion Criteria:\n\n* History of hypersensitivity or allergy to ciclopirox\n* Had any skin condition that would interfere with the diagnosis or assessment of tinea pedis\n* Had a history of dermatophyte infecton unresponsive to antifungal treatment\n* Had a history of alcoholism, drug abuse, or problems that would likely have made the subject unreliable for the study\n* Had any condition or used any medication that, in the opinion of the Investigator, might have interfered with the conduct or results of the study or placed the prospective subject at increased risk\n* Was unwilling to sign the informed consent\n* Female who was pregnant or lactating","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects in Each Treatment Group With Therapeutic Success","description":"Both Mycological Cure (KOH wet mount negative and fungal culture negative) and Clinical Cure were required to achieve Therapeutic Success","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"95","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Mycological Cure","description":"Mycological Cure (KOH wet mount negative and fungal culture negative","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"133","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Clinical Cure","description":"Clinical Cure was defined as a signs and symptoms score of \\<1 for erythema; \\<1 for scaling; and 0 for pruritus, maceration, fissuring/cracking, and burning/stinging; as well as an assessment that no additional antifungal therapy was required to treat the subject's current episode of tinea pedis","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"106","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":224},"commonTop":[]}}}